The life-changing impact of newborn screening is set to expand beyond spinal muscular atrophy (SMA) from 2027. With this major step forward for affected families in sight, calls are growing to include other severe genetic conditions, such as Duchenne muscular dystrophy (DMD), in the screening programme.
According to Dr Janet Hoskin, an Associate Professor at the University of East London, while early diagnosis for SMA will significantly improve the quality of life for those affected, conditions like DMD are often overlooked. Approximately 100 boys are born with DMD in the UK each year, a condition characterised by progressive muscle weakness. Unfortunately, diagnosis is not always straightforward and can take years, leaving families to endure uncertainty and multiple consultations.
Research conducted by Dr Hoskin, involving families affected by DMD and organisations such as Duchenne UK, highlights the need for early detection. Delayed diagnoses can prolong anxiety for families and mean missed opportunities for early intervention. New treatments, like Givinostat, offer hope for some young people with DMD, but their effectiveness is significantly enhanced when detected early.
Early diagnosis also provides families with crucial information to access specialist care and support networks much sooner. It allows parents to plan for their child's future, navigate the complexities of disability support services, and secure necessary help without lengthy battles. The current system often leaves families facing struggles to receive assistance, a burden that could be eased by proactive screening.
The success of campaigners in securing newborn screening for SMA demonstrates the power of advocacy. Dr Hoskin hopes this milestone will spark a broader national conversation about expanding screening to include other rare genetic conditions. She stresses that every child deserves the best possible start in life and every family should have access to timely diagnosis, comprehensive support, and opportunities to thrive.
Expanding newborn screening would align with the NHS's commitment to improving outcomes for children with rare diseases and could reduce the emotional and financial strain on families and the healthcare system. The National Screening Committee reviews conditions periodically, considering factors such as condition severity, treatment availability, and test accuracy.